ScrutarSign up free

JNJ SEC Filings

SEC filings for JNJ. Annual and quarterly reports, 8-K events,
Form 4 insider filings and 13D/G stake disclosures.

All10-K10-Q8-KForm 413D/GLast 12 months
FormFiledAccession
4Taubert Jennifer LEVP, WWC. Innovative MedicineAug 18, 2026EDGAR
4Duato JoaquinCEO and Chairman of the BoardAug 14, 2026EDGAR
4Duato JoaquinCEO and Chairman of the BoardAug 7, 2026EDGAR
4Forminard ElizabethEVP, Chief Legal OfficerAug 7, 2026EDGAR
8-KAug 4, 2026EDGAR
8-KJul 29, 2026EDGAR
8-KJul 28, 2026EDGAR
10-QJul 23, 2026EDGAR
4Broadhurst VanessaEVP, Global Corp AffairsJul 21, 2026EDGAR
8-KAIJohnson & Johnson filed an 8-K to report its second quarter 2026 sales and earnings results for the period ended June 28, 2026, via an attached press release and supplementary financial data.Jul 15, 2026EDGAR
4Wengel Kathryn EEVP, Chief TO and Risk OfficerJun 12, 2026EDGAR
4REED JOHN CEVP, Innovative Medicine, R&DMay 4, 2026EDGAR
SC 13GVanguard Capital ManagementMay 1, 2026EDGAR
8-KApr 27, 2026EDGAR
10-QApr 22, 2026EDGAR
8-KApr 14, 2026EDGAR
SC 13G/AamendedJOHNSON & JOHNSONApr 13, 2026EDGAR
SC 13G/AamendedJohnson & Johnson Innovation - JJDC, Inc.Apr 13, 2026EDGAR
SC 13G/AamendedVANGUARD GROUP INCMar 26, 2026EDGAR
4Decker Robert JVP Corporate ControllerMar 3, 2026EDGAR
4Schmid TimothyEVP, WW Chair, MedTechFeb 23, 2026EDGAR
4Swanson James D.EVP, CIOFeb 19, 2026EDGAR
4Wengel Kathryn EEVP, Chief TO and Risk OfficerFeb 19, 2026EDGAR
4Mulholland KristenEVP, Chief HR OfficerFeb 19, 2026EDGAR
4Wolk Joseph JExec VP, CFOFeb 19, 2026EDGAR
4Decker Robert JVP Corporate ControllerFeb 19, 2026EDGAR
4REED JOHN CEVP, Innovative Medicine, R&DFeb 19, 2026EDGAR
4Forminard ElizabethEVP, Chief Legal OfficerFeb 19, 2026EDGAR
4Taubert Jennifer LEVP, WWC. Innovative MedicineFeb 19, 2026EDGAR
4Schmid TimothyEVP, WW Chair, MedTechFeb 19, 2026EDGAR
4Duato JoaquinCEO and Chairman of the BoardFeb 19, 2026EDGAR
4Broadhurst VanessaEVP, Global Corp AffairsFeb 19, 2026EDGAR
4Schmid TimothyEVP, WW Chair, MedTechFeb 11, 2026EDGAR
10-KFeb 11, 2026EDGAR
4Mulholland KristenEVP, Chief HR OfficerFeb 10, 2026EDGAR
4Wengel Kathryn EEVP, Chief TO and Risk OfficerFeb 10, 2026EDGAR
4Forminard ElizabethEVP, Chief Legal OfficerFeb 6, 2026EDGAR
SC 13G/AamendedVANGUARD GROUP INCFeb 5, 2026EDGAR
4Duato JoaquinCEO and Chairman of the BoardJan 28, 2026EDGAR
8-KAIJohnson & Johnson filed an 8-K disclosing its fourth quarter and full year 2025 sales and earnings results via press release dated January 21, 2026.Jan 21, 2026EDGAR
SC 13G/AamendedJOHNSON & JOHNSONJan 13, 2026EDGAR
SC 13G/AamendedJohnson & Johnson Innovation - JJDC, Inc.Jan 13, 2026EDGAR
4/AJohnson & Johnson Innovation - JJDC, Inc.Jan 8, 2026EDGAR
4MORIKIS JOHN GDec 1, 2025EDGAR
4Johnson & Johnson Innovation - JJDC, Inc.Nov 25, 2025EDGAR
4Johnson & Johnson Innovation - JJDC, Inc.Nov 14, 2025EDGAR
4Johnson & Johnson Innovation - JJDC, Inc.Nov 10, 2025EDGAR
10-QOct 22, 2025EDGAR
4REED JOHN CEVP, Innovative Medicine, R&DOct 20, 2025EDGAR
8-KOct 14, 2025EDGAR
8-KAIJohnson & Johnson announced the election of John Morikis, former Executive Chairman, President and CEO of The Sherwin-Williams Company, to its Board of Directors effective September 8, 2025.Sep 8, 2025EDGAR
4Taubert Jennifer LEVP, WWC. Innovative MedicineSep 5, 2025EDGAR
4Forminard ElizabethExecutive VP, General CounselSep 3, 2025EDGAR

SEC filings for companies related to JNJ

LLYELI LILLY & CoPFEPFIZER INCPEPPEPSICO INCABBVAbbVie Inc.METAMeta Platforms, Inc.HDHOME DEPOT, INC.IBMINTERNATIONAL BUSINESS MACHINES CORPSBUXSTARBUCKS CORP

Never miss a JNJ filing.

Get an email when JNJ files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.

Free foreverNo account requiredOne-click unsubscribe

Protected by reCAPTCHA. Privacy & Terms

Source: SEC EDGAR.